Ads
related to: lipitor pfizer astellas dosage information- Co-Pay Program
Resources
to Support Your Patients
- Dosing & Administration
Efficacy, Safety, and Dosing
Information for HCPs
- Safety
Safety Profile - Learn About
Adverse Patient Reactions
- Trial Results
See Clinical Data
and Trial
- Request Samples
Get patients started
with a 14-day sample
- Resources
More Information
For Your Practice
- Co-Pay Program
consumereview.org has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]
In 1996, Warner-Lambert entered into a co-marketing agreement with Pfizer to sell Lipitor, and in 2000, Pfizer acquired Warner-Lambert for $90.2 billion. [116] [106] [112] [113] Lipitor was on the market by 1996. [114] [117] By 2003, Lipitor had become the best selling pharmaceutical in the United States. [110]
The best-selling statin is atorvastatin, also known as Lipitor, which in 2003 became the best-selling pharmaceutical in history. [12] The manufacturer Pfizer reported sales of US$12.4 billion in 2008. [13] Patient compliance with statin usage is problematic despite robust evidence of the benefits. [14] [15]
Pfizer (NYS: PFE) used to sell Lipitor exclusively in the United States. And it was a huge component of the company's revenue and earnings. Honest. I swear. You certainly wouldn't know it from the ...
Lately, almost every day we've heard of a new Pfizer (NYS: PFE) strategy for hanging on to Lipitor sales after the drug faces generic competition. Discounts, co-pay cards, rebates, conversion to ...
Torcetrapib (CP-529,414, Pfizer) was a drug being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease.Its development was halted in 2006 when phase III studies showed excessive all-cause mortality in the treatment group receiving a combination of atorvastatin (Lipitor) and torcetrapib.
Ad
related to: lipitor pfizer astellas dosage information